Related references
Note: Only part of the references are listed.Exploring the Relationship between Frailty, Functional Status, Polypharmacy, and Quality of Life in Elderly and Middle-Aged Patients with Cardiovascular Diseases: A One-Year Follow-Up Study
Elisabeta Ioana Hiriscau et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
The Role of Oxidative Stress in the Aging Heart
Luana U. Pagan et al.
ANTIOXIDANTS (2022)
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy
Takao Katoh et al.
LUTS-LOWER URINARY TRACT SYMPTOMS (2021)
β 3 Adrenergic Receptor Stimulation Promotes Reperfusion in Ischemic Limbs in a Murine Diabetic Model
Kristen J. Bubb et al.
FRONTIERS IN PHARMACOLOGY (2021)
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
Veena Hoffman et al.
DRUG SAFETY (2021)
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)
Adrian Wagg et al.
EUROPEAN UROLOGY (2020)
Association between anticholinergic drug burden and mortality in older people: a systematic review
Sheraz Ali et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
Asad Makhani et al.
CLINICAL INTERVENTIONS IN AGING (2020)
Quality of Life and Frailty Syndrome in Patients with Atrial Fibrillation
Agnieszka Slawuta et al.
CLINICAL INTERVENTIONS IN AGING (2020)
Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis
Greta Lozano-Ortega et al.
DRUGS & AGING (2020)
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
Osamu Yamaguchi et al.
INTERNATIONAL JOURNAL OF UROLOGY (2019)
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial
Michael A. Weber et al.
BLOOD PRESSURE MONITORING (2018)
Cardiovascular Safety of the 3-Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
William B. White et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis
Hsiao-Ling Chen et al.
WORLD JOURNAL OF UROLOGY (2018)
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)
Marcus J. Drake et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2017)
An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects
Marcel van Gelderen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder
Vincent Tse et al.
BJU INTERNATIONAL (2016)
Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
Christopher R. Chapple et al.
EUROPEAN UROLOGY (2013)
Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
Vik Khullar et al.
EUROPEAN UROLOGY (2013)
Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
Victor W. Nitti et al.
JOURNAL OF UROLOGY (2013)
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
E. Ann Gormley et al.
JOURNAL OF UROLOGY (2012)
Prevalence and Effect on Health-Related Quality of Life of Overactive Bladder in Older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study
Chris C. Sexton et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Symptom assessment tool for overactive bladder syndrome- Overactive bladder symptom score
Yukio Homma et al.
UROLOGY (2006)
Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women
GD Chen et al.
NEUROUROLOGY AND URODYNAMICS (2003)
Prevalence and burden of overactive bladder in the United States
WF Stewart et al.
WORLD JOURNAL OF UROLOGY (2002)
The standardisation of terminology of lower urinary tract function: Report from the of the International Standardisation Sub-Committee Continence Society
P Abrams et al.
NEUROUROLOGY AND URODYNAMICS (2002)
How widespread are the symptoms of an overactive bladder and how are they managed?: A population-based prevalence study
I Milsom et al.
BJU INTERNATIONAL (2001)
Share Paper
